Selegiline tablets

S. A. Qureshi and I. J. McGilveray, Dissolution studies of selegiline tablets, Pharmacopeial Forum, 1973 (1991). 

The selective irreversible MAO-B inhibitors enhance dopamine activity by preventing dopamine degradation. These drugs sometimes interact like older non-selective MAOls, and the reader is cross-referred to the information under MAOls when appropriate. Selegiline undergoes rapid first-pass metabolism to produce arnfetamine metabolites. A bueeal tablet has been developed, whieh markedly reduees this first-pass metabolism, and is consequently given as a smaller dose. 

Selegiline hydrochloride tablets USP. Endo Generic Products. US Prescribing information, November 2001. 

Selegiline [(/ )(-)-W,a-dimethyl-W-(2-propynyl)benzeneethanamine, Elde-pryl. Deprenyl, 1] is a phenethylamine derivative which is pharmacologically active in the levo form. It is indicated as adjuvant treatment with levo-dopa in Parkinson s disease, and is supplied as a 5 mg tablet of selegiline hydrochloride. It belongs to the class of type B inhibitors of monoamine oxidase (MAOI-B). At high doses (>40 mg/day in man), selegiline loses its MAOI-B specificity and also inhibits MAO-A. 

---